Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Prime Medicine, Inc. publishes a filing, an earnings call transcript or a press release.

Get PRME alerts

About Alan Ryan

Alan Ryan is recorded as CEO at Prime Medicine, Inc. (PRME). Alan Ryan has spoken on 5 investor events across 1 company, most recently for Prime Medicine, Inc. on November 16, 2026. Prime Medicine, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Prime Medicine, Inc. includes Allan Reine (CEO and Board Member), Allan Reine, M.D. (CEO and Board Member), Jeffrey Marrazzo (Chairman) and 3 others.

Alan Ryan on recent calls

“I just used up about four seconds of that. But Prime Medicine, I think about it as really a next-generation gene-editing technology. You can really think about it as the most versatile way to edit the genome.”
CEO, Jefferies London Healthcare Conference ·
“I think we're all very lucky to kind of be alive to see these technologies in others as they advance. I know they're just incredible, as you think of, where we were 20 years ago and where we are today.”
CEO, Morgan Stanley 24th Annual Global Healthcare Conference ·
“So Prime is a gene editing, Prime editing is a gene editing technology that was founded out of David Liu's lab. So this is a groundbreaking technology that really, you can think about it as the most versatile and the safest way to edit the genome.”
CEO, H.C. Wainwright 28th Annual Global Investment Conference ·
“Yeah, so where we stand today is, you know, if you think about it, the company was founded, you know, five, six years ago, really to carry forward this great technology, which is prime editing.”
CEO, Goldman Sachs 47th Annual Global Healthcare Conference ·
“Yeah, so Prime Medicine is a company that's focused on progressing our technology, which is prime editing.”
CEO, Jefferies Global Healthcare Conference 2026 ·

Affiliation history

Company network

Leadership on record at Prime Medicine, Inc.

Recent activity